血液滤过治疗重型肝炎中白介素12变化的研究  

The Changes of Interleukin 12 in Hemofiltration Treatment of Hepatitis Patients

作　　者：俞海英[1] 杨毅军[1] 张宁[1] 刘新钰[1] 方之勋[1] 

机构地区：[1]东南大学医学院附属南京第二医院,江苏南京210003

出　　处：《临床肝胆病杂志》2002年第2期118-119,共2页Journal of Clinical Hepatology

摘　　要：通过人工肝支持治疗（ＡＬＳＳ）重型肝炎，了解血液滤过（Ｈｅｍｏｆｉｌｔｒａｔｉｏｎ ＨＦ）前后白介素 １２（ＩＬ－１２）、肝功能、ＴＮＦ－α的变化。探讨ＩＬ－１２的临床价值。治疗组１８例为血液滤过＋基础综合治疗；对照组２０例仅予基础综合治疗。治疗组治疗后血清ＩＬ－１２为（２８３．８８■２７０．４４），Ｐ＜０．０１。与治疗前比治疗后血清ＩＬ－１２明显升高。对照组治疗前后ＩＬ－１２含量无显著变化。治疗组前后肝功能及ＴＮＦ－α无显著变化。血液滤过可使细胞因子ＩＬ－１２升高，对重型肝炎肝衰竭有保护作用。血液滤过后血清ＩＬ－１２含量的变化可作为评价重型肝炎预后的指标之一。To understand the cytokine changes of hepatiitis patients that were hemofiltrated by artificial liver support sys- tem(ALSS) and investigate the clinical significance, we detected the changes of Interleukin 12(IL-12) and tumor necrosis factor (TNF). Eighteen patients were operated by hemofiltration and basis treatment as treament group (1st group) but another 20 patients were suffered basic treatment only as contrast group (2nd group). The levels of IL-12 and TNF were detected during treaing. The IL-12 of serum was increased after the treatment course (from (107 .9 ■ 48.44) to (287. 88 ■ 270.44)pg/ml,p < 0.01 )in 1st group but that was not changed in 2nd group. TNF was not changed in two groups. Hemofiltration can increases serums IL-12 in severe hepatitis patients. IL-12 has protective effects on hepatic fail- ure. The change of IL-12 levels is one of prognostic standard.

关 键 词：重型肝炎 血液滤过 IL-12 

分 类 号：R575.1[医药卫生—消化系统]